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Summary 
Despite seven hundred thousand new medical references last year, the relationship 
between a given set of medical features and specific pathophysiology, treatment, and 
criteria of improvement is often weak. Moreover, the generalization of evidences 
obtained in specific settings may lead to under-treat or to over-treat a significant 
proportion of patients. We expose an application of the cybernetic loop, based on 
traditional medical steps: nosology, semeiology, pathophysiology, therapy and on the 
four transitions between these steps. This approach leads to formulate eight basic 
questions evaluating the steps in terms of reproducibility and the transitions in terms of 
predictivity. We detail two practical applications: 1) the evaluation of a medical decision 
(implantation of an internal cardioverter-defibrillator) and 2) the evaluation of a 
specific study (EPHESUS). Using this loop allows to determine clearly when evidence is 
lacking and/or to which extend an evidence really increases the medical knowledge or 
just creates a market. 
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 Medical knowledge can be schematically scored by four successive degrees of 
reliability: belief, logic, experience, and evidence.1 Is evidence the final step? This is 
questionable.2,3 One can hardly generalize a physiologic mechanism observed in a specific 
setting. On the contrary, a given therapy, effective or ineffective in a large population, may 
have large inter-individual differences. Moreover, with improving methodology, past 
evidence may no longer be considered valid today.4,5 Therefore, in practice, it is often 
necessary to deal with the different degrees of knowledge.1,6  
 
Modelization may represent a step forward; giving, whenever possible, more stable, more 
analytic and more didactic expression of knowledge.7 Despite being underused in clinical 
medicine, this approach has proven to be fruitful in radiology, 8,9 ,biology,10,11 and many other 
scientific disciplines. Clinicians may have interest in sharing some tools with researchers in 
modelization. The cybernetic (or systemic) loop is a comprehensive schema of any system 
involving control and decision,12,13 that any physician intuitively knows. Its formalization can 
help them in: 1) making a hierarchy between numerous elementary pieces of knowledge, and 
including them into a comprehensive schema for decision making; 2) determining when new 
evidences are really necessary to markedly improve practical decisions.14,15 Since medical 
research is increasingly granted by the industry, distinguishing medical knowledge from 
marketing interest is of growing importance.16 
 
This article introduces clinicians to a simple cybernetic loop applied to pieces of evidence 
found in the literature, with no attention to their methodology. These examples illustrate the 
usefulness and didactic interest of this loop in scoring the reliability of any medical decision. 
This is an attempt to take Evidence-Based Medicine (EBM) to a larger concept that can be 
defined as Intelligence-Based Medicine (IBM). 
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The Cybernetic loop 
 
A cybernetic loop basically includes four steps as shown in Figure 1: 1) delimitation 
of the domain where the loop is relevant, 2) definition of the input items needed and sufficient 
to describe the reasoning process, 3) formalization of the reasoning process, 4) choice and 
definition of actions triggered by the reasoning process.17,18 
 
 
Figure 1. A simple cybernetic loop. Boxes are the steps of the loop. Arrows represent the 
transitions between steps. The transition between the domain (step 1) and the loop (entirely 
included in the domain) is represented by a large angled arrow. 
 
These four steps correspond schematically to well known medical translations: nosology, 
semeiology, pathophysiology, and therapy, respectively. An additional step, referring to as 
“output items” or “diagnosis” in Medicine may be added between “reasoning process” and 
“action”. When the reasoning process is complex or poorly understood, or when there is no 
clear action, a set of output (diagnostic) items is merely required for inter-observer 
communication. In this situation, frequently observed in systemic diseases for example, the 
loop may be difficult to close due to a lack of knowledge and therefore, the cybernetic 
approach may have limited interest. In contrast, when a clear pathophysiology leads to clear 
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therapy, a diagnostic step is unnecessary and can only be viewed as a potential loss of 
information.  
Practical applications of the loop in Medicine 
Any system control and decision may be analyzed with a cybernetic loop (Figure 2). 
Since degrees of knowledge are cumulative, the reliability attributable to each step and 
transition may be schematically scored by a pictogram representing the actual knowledge as a 
sum of layers stacked like the layers of the brain from archeo knowledge (belief) to neo 
knowledge (evidence).   
 
Figure 2. The cybernetic loop applied to Medicine. For each of the eight elements of the 
schema, the reliability of the available knowledge can be scored using a pictogram. The 
knowledge of the transition between the domain and the loop has been enlarged to show the 
four layers distinctly 
 
Two examples, shown below, are intended to clarify the practical interest of the cybernetic 
loop for medical purpose; first in evaluating a medical process, then in evaluating a specific 
study. The reliability of a given decision is tested simply by formulating four basic questions 
on the four steps and four basic questions on the four transitions. It is likely to enter the loop 
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at any step, but it is often convenient to first identify the pathophysiologic process. From any 
start point, other steps and transitions are determined subsequently. Basically, steps (boxes in 
all figures) are explored in terms of reproducibility (is the box clearly delimited?) and 
transitions (arrows in all figures) are explored in terms of predictivity (sensitivity and 
specificity, see figure 3). The global reliability of the loop is that of its lowest element. A 
negative answer in one element invalidates the reliability of the whole loop.  
 
 
Figure 3. Representation of a part of the loop restricted to two steps with their transition.
Boxes are the steps of the loop, arrows are the transitions. Black arrow = sensitive and 
specific transition. Dotted black arrow, lack of sensitivity, dotted grey arrow = lack of 
specificity. 
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a) Evaluation of a medical process 
The ACC/AHA/HRS 2008 guidelines recommend implanting an internal 
cardioverter-defibrillator (ICD) to patients having ischemic or non ischemic 
cardiomyopathy with left ventricle ejection fraction 35% and New York Heart 
Association functional class II-III despite appropriate treatment.19 Our purpose is to 
evaluate the global reliability attributable to this decision, based on the actual 
knowledge. In this example, the occurrence of a major arrhythmia leading to death is the 
pathophysiologic process that we want to treat. For clarity, the example is restricted to 
ventricular fibrillation and electric shock delivery but the same reasoning can be made 
for other major arrhythmias and the various algorithms used to stop them before shock 
delivery. Hence, the review starts at the pathophysiologic step. 
 
1. Step pathophysiology. Is the pathophysiologic process reproducibly formalized?
Ventricular fibrillation is a chaotic electrical re-entrant wave front leading to cardiac 
pump failure, then to tissue dysoxia (especially brain), and ultimately death.20,21 
Spontaneous recovery of ventricular fibrillation is very exceptional.22,23 Any ventricular 
fibrillation will lead to death with a degree of evidence (Figure 4). 
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Figure 4: Cybernetic loop applied to “implanting an ICD”. Ventricular fibrillation 
leads to death with a degree of positive evidence leading to add four layers of 
knowledge in the pictogram of the box “pathophysiology”.  When the answer to the 
question is negative, the pictogram is inverted (transition between domain and loop). 
The dotted arrow indicates that shock may be delivered without major arrhythmia (low 
specificity).  
 
2. Step semeiology. Are input items reproducibly defined?
Input items are not clinical data in this example but a set of heart electric signals sensed 
by the ICD to determine the presence or not of ventricular fibrillation. The 
reproducibility of this set of items is debatable. We can score it at a belief degree 
because we have no other choice than accepting the manufacturer’s guarantee. 
However, reliable technologies are available.24-26 Even though unpublished, internal 
studies are required for regulatory approval. We can therefore admit a degree of 
experience. 
3. Step therapy. Is the action (delivery of an internal electric shock) reproducible?  
Electric shock is reproducibly delivered until the ICD battery contains enough power. 
There are similar concerns as that for question 2, but considering that it is a widely used 
technology, we can admit again a degree of evidence. 
 
4. Transition from semeiology to pathophysiology. Is the set of input items (electric 
items) sensitively and specifically linked with the pathophysiologic process (death from 
ventricular fibrillation)?  
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This transition is sensitive if eventual disconnection of the sensors can be eliminated. It 
is specific if artefacts are properly filtered. It depends also on the ability of the system to 
determine if the electric signal is chaotic or not. For the same reasons as in question 2, 
let’s admit a degree of experience. 
 
5. Transition from pathophysiology to therapy. Is the pathophysiologic process (death 
from ventricular fibrillation) sensitively and specifically linked with therapy (shock 
delivery)?  
This transition is sensitive because it has been shown that any ventricular fibrillation is 
followed by shock delivery. In contrast, the specificity is not perfect because 
inappropriate shock is possible.27,28 In our schema, this is indicated by another arrow 
going in the box “therapy” (figure 4). The degree of knowledge is evidence for both 
high sensitivity and low specificity.  
  
6. Transition from therapy to semeiology. Is therapy (shock) sensitively and specifically 
active on input items (a chaotic electric signal become not chaotic)?  
Internal electric shock is proved to be efficient in treating ventricular fibrillation.29 It is 
also exceptional that the ECG returns to normal when no shock is delivered.22,23 Hence, 
the degree is evidence. 
 
7. Step domain (nosology). Is the domain (ICD indications) determined reproducibly?  
ICD indications have been consensually established, based on specific criteria for 
different cardiac pathologies.19 The reproducibility of these individual criteria such as 
left ventricle ejection fraction 35%, or high stages of congestive heart failure has been 
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evaluated and found acceptable, 30,31 However, no studies have been designed to 
evaluate the reproducibility of specific associations of criteria. Then, we can consider 
this step as moderately reproducible with a degree of experience. 
 
8. Transition from domain to loop. Is the domain sensitive and specific to the studied 
loop?
Using the ICD indications above, the important question turned out to be: are all 
patients at risk of ventricular fibrillation going to be implanted and are all implanted 
patients going to experience ventricular fibrillation? The answer is no with a degree of 
evidence. In MADIT II, 70% of the implanted patients will never experience ventricular 
fibrillation.32 In these patients, the process is unnecessarily harmful because the surgical 
risk and discomfort are not balanced.  
 
Finally, it is not surprising to find that, except its transition with the domain, the ICD 
loop is reliable with a global degree of experience since it is an automatic device, and 
therefore, uses a high level of modelization. Our approach allows anyone to point out 
quickly where new evidences are necessary as reported by experts.33,34 Confidence with 
ICD would benefit by reporting the reliability of ICD electrical signal acquisition and 
analysis. Improving the specificity of shock delivery is also necessary and may be 
linked with better signal analysis. The major weakness is the poor link between the loop 
and the domain. Then, most of the patients with ICD will not use it. Optimizing the 
decision of implanting an ICD would require more reproducible and more specific 
domain definition (criteria for implantation). As examples, it has been suggested that 
black people may have no benefit of an ICD implanted according to MADIT II 
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indications.35 Also in SCDHeFT, benefit from ICD was only seen in NYHA functional 
class II patients and not in class III/IV patients.30  
 
a) Evaluation of a study 
The cybernetic loop is also useful to weigh the interest of a specific study. To 
illustrate this usefulness, we will take the example of EPHESUS. This study published 
in the New England Journal of Medicine proved that an anti-aldosterone therapy by 
Eplerenone improves survival in patients with acute myocardial infarction complicated 
by left ventricular dysfunction and heart failure.36 In this example, we can start with the 
step therapy. The basic questions seem in a) are not reformulated. 
 
1. Step therapy: Pharmacological properties and therapeutic effects of Eplerenone were 
not investigated in EPHESUS, but we know from other studies that they are stable 
although a limited number of humans were studied.37,38 In EPHESUS, observance was 
good. Therefore, we can admit that the therapeutic effect of Eplerenone is reproducible 
with a degree of evidence. 
 
2. Step pathophysiology: The question that arises is: on which pathophysiologic process 
is Eplerenone active? The problem is that Eplerenone is suspected to impact at least 
three different pathophysiologic processes in addition to its well known potassium 
sparing effect: myocardial wall remodelling,39 conduction tissue (electric) 
remodelling,40 and endothelial protection, with coronary circulation improvement.41 
Then, in our cybernetic loop, we are obliged to consider three different 
“pathophysiologic” boxes (Figure 5). The degree of knowledge attributable is different 
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for the three processes: We can admit “evidence” for wall remodelling, “experience” for 
coronary perfusion improvement, and “experience” for electric remodelling. In order to 
simplify our schema, we can admit here that hypokaliemia is not a potentially fourth 
pathophysiologic step since correcting eventual  
 
 
Figure 5. The EPHESUS loop shows that it is a very complex loop. Three different 
patho-physiologic boxes are necessary to represent the pathophysiologic processes on 
which the therapeutic action is based. Grey arrows represent transition from one or 
many other loops. 
 
3. Step semeiology. Inclusion criteria in EPHESUS were: 1) recent myocardial 
infarction, 2) left ventricle ejection fraction< 45%, and 3) Clinical signs of congestive 
heart failure. There is some confusion here; “Recent infarction” is not changed by the 
therapeutic action and is consequently at a domain level, while the remaining two 
criteria susceptible to recovery by therapy, are input items. These two criteria are simple 
and acceptably reproducible.42,43 Although their reproducibility in association has never 
been investigated, we can admit that few patients with the criteria have been excluded, 
while few patients without the criteria have been included (degree of experience). 
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4. Transition from semeiology to pathophysiology: Although recent severe infarction is 
likely to act very frequently on the three suspected pathophysiologic processes, these 
processes may be observed in situations without congestive heart failure and left 
ventricle ejection fraction <45%. Then the transition is not specific with a degree of 
experience. 
 
5. Transition from pathophysiology to therapy: Are the three pathophysiologic 
processes sensitively and specifically linked with therapy by Eplerenone? We know 
little about electric remodelling therefore we cannot estimate the sensitivity and 
specificity of this transition. We do know that wall remodelling may justify other drugs 
therapy than Eplerenone (converting enzyme inhibitors for example). For this reason, 
the transition between wall remodelling and Eplerenone is not sensitive. However, this 
drawback is limited because inclusion criteria, recommended using converting enzymes 
inhibitors. Similarly the transition between the endothelium effect and Eplerenone is not 
sensitive, many other mechanisms are involved.44 The specificity is also poor because 
other physiologic processes than the three processes involved here may be changed by 
Eplerenone, such as blood pressure and kidney function. In light of this, in EPHESUS, 
the link between known pathophysiologic processes and therapy is neither sensitive, nor 
specific (degree of evidence). 
  
6. Transition from therapy to semeiology: The endpoint of the study was not the 
recovery of input items (impaired left ventricle ejection fraction and congestive heart 
failure), but survival; a global criteria on which the studied pathophysiologic processes 
and others are effective. Although improvement in survival is an important final goal, it 
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must be obtained by improving the input items of the pathophysiologic process. If this 
link is not ascertained Eplerenone may increase survival by improving other 
unsuspected pathophysiologic processes that can be found in this domain but also in 
other domains. Alternatively, Eplerenone may have an inconstant effect hiding 
important unpredictable inter-individual differences. Therefore many patients may be 
under treated or over treated. 
 
7. Step Domain: Although the domain is not clearly identified in EPHESUS, we have 
seen that one of the inclusion criteria (recent infarction) was not at an input item level 
but at a domain level. So, the domain definition can be considered as being ‘recent 
infarction” and being acceptably reproducible with a degree of evidence.45 
 
8. Transition Domain-Loop: Most patients with recent infarctions are likely to have the 
three identified physiological processes. The transition is then sensitive. However, other 
domains such as dilated cardiomyopathy, myocarditis, or ischemic cardiomyopathy 
without recent infarction may act on the same three pathophysiologic processes. This 
transition is not specific (degree of evidence). 
 
Hence, in this example, although Eplerenone increases survival, EPHESUS considered 
alone brings little intelligence as shown in figure 4. The link between pathophysiology 
and therapeutic action is neither sensitive nor specific. Even combined with past 
medical knowledge, EPHESUS did not tell us if all patients of the studied population 
are likely to benefit by Eplerenone or if the global result hides significant subpopulation 
discordances. In other words, Eplerenone is statistically good for the EPHESUS 
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population but we are not sure that it is good for each individual patient and that other 
patients not studied may not benefit from Eplerenone. Subsequently EPHESUS calls for 
additional studies.  
 
 
Although more and more studies provide clinicians with undisputable pieces of 
evidence, the practical usefulness of these evidences in the daily practice is sometimes 
low. A medical application of the cybernetic loop, based to eight basic questions, may 
help in including evidences in a comprehensive schema for medical decision making 
and in determining which new research needs high priority. For better insertion in an 
intelligence-based medicine, we would expect any new study to initially recall the steps 
and transitions that are already controlled, to detail the methods of steps and transitions 
that the study intends to improve, and to summarize in conclusion which studies remain 
to be done. Because any medical domain is also a medical market, this tool will also 
throw light on when the loop is working for improving the knowledge or for enlarging a 
market. 
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